b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia

被引:45
作者
Norbury, LC
Clark, RE
Christmas, SE
机构
[1] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England
[2] Royal Liverpool Univ Hosp, Dept Immunol, Liverpool L7 8XP, Merseyside, England
关键词
chronic myeloid leukaemia; cytotoxic T lymphocytes; immunotherapy;
D O I
10.1046/j.1365-2141.2000.02090.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peptide sequences spanning the BCR-ABL protein junction potentially constitute novel leukaemia-specific antigens. 9-mer b3a2 fusion peptides have been reported to bind with high affinity to HLA-A3, -A11 and -B8. We have studied the effect of b3a2 BCR-ABL junctional peptides on the cytotoxic T-cell (CTL) response against normal and chronic myeloid leukaemia (CML) cells. Antigen-presenting cells (APCs) were prepared from HLA-A3- or -B8-positive peripheral blood mononuclear cells (PBMCs) by incubation with phytohaemagglutinin (PHA) and interleukin (IL)-2 for 7 d. These APCs were pulsed with the respective b3a2 junctional peptide in the presence of beta(2)-microglobulin and were then used to challenge autologous PBMCs at 7-d intervals in the presence of IL-2, IL-6, IL-7 and IL-12. On subsequent exposure to target cells (either further pulsed normal APCs or unpulsed CML cells), specific HLA-restricted CTL responses were observed against all HLA-A3/-B8 matched normal target cells tested, but not to targets that were HLA mismatched, Cytotoxicity was also induced against HLA-A3/-B8 unpulsed CML cells, but not against unmatched CML cells. These data indicate (i) that endogenous BCR-ABL junctional peptides map be presented by CMI, cells and (ii) that exogenous peptides are potential stimulators of autologous antileukaemic CTLs.
引用
收藏
页码:616 / 621
页数:6
相关论文
共 35 条
[1]   IMMUNOLOGICAL CHARACTERIZATION OF THE TUMOR-SPECIFIC BCR ABL JUNCTION OF PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOID-LEUKEMIA [J].
BARRETT, J ;
GUIMARAES, A ;
CULLIS, J ;
GOLDMAN, JM .
STEM CELLS, 1993, 11 :104-108
[2]   SPECIFIC BINDING OF LEUKEMIA ONCOGENE FUSION PROTEIN-PEPTIDES TO HLA CLASS-I MOLECULES [J].
BOCCHIA, M ;
WENTWORTH, PA ;
SOUTHWOOD, S ;
SIDNEY, J ;
MCGRAW, K ;
SCHEINBERG, DA ;
SETTE, A .
BLOOD, 1995, 85 (10) :2680-2684
[3]   Specific human cellular immunity to bcr-abl oncogene-derived peptides [J].
Bocchia, M ;
Korontsvit, T ;
Xu, Q ;
Mackinnon, S ;
Yang, SY ;
Sette, A ;
Scheinberg, DA .
BLOOD, 1996, 87 (09) :3587-3592
[4]   Peptides derived from the whole sequence of BCR-ABL, bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes [J].
Buzyn, A ;
Ostankovitch, M ;
Zerbib, A ;
Kemula, M ;
Connan, F ;
Varet, B ;
Guillet, JG ;
Choppin, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (08) :2066-2072
[5]  
CHAMPLIN R, 1995, EXP HEMATOL, V23, P1148
[6]   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].
Choudhury, A ;
Gajewski, JL ;
Liang, JC ;
Popat, U ;
Claxton, DF ;
Kliche, KO ;
Andreeff, M ;
Champlin, RE .
BLOOD, 1997, 89 (04) :1133-1142
[7]  
Coulie Pierre G., 1993, Current Opinion in Oncology, V5, P1043, DOI 10.1097/00001622-199311000-00016
[8]  
DATTA AR, 1994, BONE MARROW TRANSPL, V14, P517
[9]   Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation [J].
Dermime, S ;
Mavroudis, D ;
Jiang, YZ ;
Hensel, N ;
Molldrem, J ;
Barrett, AJ .
BONE MARROW TRANSPLANTATION, 1997, 19 (10) :989-999
[10]   TICKLING THE TCR - SELECTIVE T-CELL FUNCTIONS STIMULATED BY ALTERED PEPTIDE LIGANDS [J].
EVAVOLD, BD ;
SLOANLANCASTER, J ;
ALLEN, PM .
IMMUNOLOGY TODAY, 1993, 14 (12) :602-609